Aptose Q1 net loss $7.6M, cash $4.1M; Hanmi acquisition delayed, TUS data at EHA

Aptose Biosciences Inc.

2026-Q1 EPS reported -$2.99

Net loss of $7.6M ($2.99/share) for Q1 2026 vs $5.5M ($2.61/share) in Q1 2025.
Cash and restricted cash $4.1M; working capital deficit $5.1M; relies on Hanmi advances to fund operations.
Hanmi acquisition delayed due to pending Korean regulatory approvals; target close May 2026 at C$2.41/share (28% premium).
TUS+VEN+AZA triplet data from TUSCANY trial selected for oral presentation at EHA2026 Congress in June.
Luxeptinib license rights returned to CGI; program winding down.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.